Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline L Paredes

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|July 24, 2020
Type I interferon antagonists in clinical development for lupusJacqueline L Paredes, Timothy B Niewold
Rheumatic Diseases Clinics of North America|July 3, 2021
T Cells in Systemic Lupus ErythematosusJacqueline L Paredes, Ruth Fernandez-Ruiz, Timothy B Niewold
Translational Research : the Journal of Laboratory and Clinical Medicine|December 22, 2020
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory diseaseRuth Fernandez-Ruiz, Jacqueline L Paredes, Timothy B Niewold
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2020
Lessons from precision medicine in rheumatologyTheresa L Wampler Muskardin, Jacqueline L Paredes, Simone Appenzeller, et al.
Current Opinion in Immunology|November 27, 2020
Type I interferon in the pathogenesis of systemic lupus erythematosusMariana Postal, Jessica F Vivaldo, Ruth Fernandez-Ruiz, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|February 3, 2022
Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19Ilona Nln, Ruth Fernandez-Ruiz, Theresa L Wampler Muskardin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 9, 2021
Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19Ilona Nln, Ruth Fernandez-Ruiz, Theresa L Wampler Muskardin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|July 24, 2020
Type I interferon antagonists in clinical development for lupusJacqueline L Paredes, Timothy B Niewold
Rheumatic Diseases Clinics of North America|July 3, 2021
T Cells in Systemic Lupus ErythematosusJacqueline L Paredes, Ruth Fernandez-Ruiz, Timothy B Niewold
Translational Research : the Journal of Laboratory and Clinical Medicine|December 22, 2020
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory diseaseRuth Fernandez-Ruiz, Jacqueline L Paredes, Timothy B Niewold
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2020
Lessons from precision medicine in rheumatologyTheresa L Wampler Muskardin, Jacqueline L Paredes, Simone Appenzeller, et al.
Current Opinion in Immunology|November 27, 2020
Type I interferon in the pathogenesis of systemic lupus erythematosusMariana Postal, Jessica F Vivaldo, Ruth Fernandez-Ruiz, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|February 3, 2022
Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19Ilona Nln, Ruth Fernandez-Ruiz, Theresa L Wampler Muskardin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 9, 2021
Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19Ilona Nln, Ruth Fernandez-Ruiz, Theresa L Wampler Muskardin, et al.
Pageof 1